Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2407801 | Vaccine | 2007 | 6 Pages |
Abstract
Former economic analyses have shown that universal mass vaccination of infants against varicella using a one-dose schedule is cost-saving in Germany. In July 2006, an MMRV combination vaccine has been approved in Germany which shall be given in a two-dose schedule. We re-analysed our former analysis with the EVITA model in order to prove whether our former conclusion that universal mass vaccination against varicella is cost-saving is still valid when using a two-dose schedule vaccine. Indeed we found that universal mass vaccination of infants against varicella with a two-dose vaccine is cost-saving from societal as well as from health care perspective.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Thomas Hammerschmidt, Helmtrud Bisanz, Peter Wutzler,